Blood-Based Biomarker Test 84% Concordant with Amyloid Brain Imaging 

A prognostic blood biomarker test (AlzoSure Predict; Diadem, Milan, Italy) for the early prediction of Alzheimer disease (AD) was found 84% concordant with brain amyloid imaging. The prognostic blood biomarker test was able to identify individuals in preclinical and early stages of AD with over 95% area under the curve (AUC) accuracy up to 6 years before clinical diagnosis. 

 Data suggest p-53 could predict progression from mild cognitive impairment (MCI) to AD.

A high concentration of U-p53AZ was already detectable at the preclinical stage, years in advance of symptom onset in individuals who progressed to AD. p53 is known to interact with phosphorylated-tau and beta amyloid proteins known to play a role in AD pathogenesis. 

These data were presented on October 5, 2021, at the Alzheimer Drug Discovery Foundation's 2021 International Conference on Alzheimer Drug Discovery by Simona Piccirella, PhD, Diadem's vice president of Product Development and Operations. Dr. Piccirella noted, "We have presented data from multiple studies showing that AlzoSure Predict can accurately identify individuals at high risk of progressing to AD early in the disease process. This new data further confirms the accuracy of AlzoSure, showing that it is highly concordant with amyloid brain imaging, the current gold standard for diagnosing AD. Unlike brain imaging, which is expensive and primarily available in specialized facilities, AlzoSure Predict requires only a simple blood draw and analysis in a clinical laboratory, making it potentially widely accessible for screening and early diagnosis of AD."